EUVIMEDEUVIMED entdecken
Open Access

Clonal Hematopoiesis of Indeterminate Potential in Crohn’s Disease and Ulcerative Colitis

Myvizhi Esai Selvan iD, Daniel I Nathan iD, Daniela Guisado iD, Giulia Collatuzzo iD, Sushruta Iruvanti iD, Paolo Boffetta iD, John Mascarenhas iD, Ronald Hoffman iD, Louis J Cohen iD, Bridget K Marcellino iD, Zeynep H Gümüş iD

Inflammatory Bowel Diseases · 01.08.2025 · 31 (8) · 2123-2133

DOI: 10.1093/ibd/izae312 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 06.01.2025. Verfasst von Myvizhi Esai Selvan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetics and Genomics, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Pl, Box 1498, New York, NY 10029, USA. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Crohn Disease, Clonal Hematopoiesis. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, Rainin Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Clonal hematopoiesis of indeterminate potential (CHIP) is the presence of somatic mutations in myeloid and lymphoid malignancy genes in the blood cells of individuals without a hematologic malignancy. Inflammation is hypothesized to be a key mediator in the progression of CHIP to hematologic malignancy and patients with CHIP have a high prevalence of inflammatory diseases. This study aimed to identify the prevalence and characteristics of CHIP in patients with inflammatory bowel disease (IBD).

Methods

We analyzed whole-exome sequencing data from 587 Crohn’s disease (CD), 441 ulcerative colitis (UC), and 293 non-IBD controls to assess CHIP prevalence and used logistic regression to study associations with clinical outcomes.

Results

Older UC patients (age > 45) harbored increased myeloid-CHIP mutations compared to younger patients (age ≤ 45) (P = .01). Lymphoid-CHIP was more prevalent in older IBD patients (P = .007). Young CD patients were found to have myeloid-CHIP with high-risk features. Inflammatory bowel disease patients with CHIP exhibited unique mutational profiles compared to controls. Steroid use was associated with increased CHIP (P = .05), while anti-TNF therapy was associated with decreased myeloid-CHIP (P = .03). Pathway enrichment analyses indicated an overlap between CHIP genes, IBD phenotypes, and inflammatory pathways.

Conclusions

Our findings underscore a connection between IBD and CHIP pathophysiology. Patients with IBD and CHIP had unique risk profiles, especially among older UC patients and younger CD patients. These findings suggest distinct evolutionary pathways for CHIP in IBD and necessitate awareness among IBD providers and hematologists to identify patients potentially at risk for CHIP-related complications including malignancy, cardiovascular disease, and acceleration of their inflammatory disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeCrohn DiseaseClonal HematopoiesisHumansFemaleMaleAdultMiddle AgedCase-Control StudiesMutationExome SequencingYoung AdultAged

Stichwörter der Autor:innen

Crohn’s diseaseclonal hematopoiesis of indeterminate potentialinflammatory pathwayssomatic mutationsulcerative colitis

Autor:innen und Institutionen

  • Department of Genetics and Genomics, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Pl, Box 1498, New York, NY 10029, USA.
  • Tisch Cancer Institute, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Pl, Box 1079, New York, NY 10029, USA.
  • Division of Pediatric Gastroenterology, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Pl, Box 1069, New York, NY 10029, USA.
  • Department of Medical and Surgical Sciences, University of Bologna, Via Zamboni, 33 - 40126, Bologna, Italy.
  • Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Pl, Box 1498, New York, NY 10029, USA.
  • Stony Brook Department of Family, Population and Preventive Medicine, Renaissance School of Medicine, 101 Nicolls Road Health Sciences Center, Level 4, Stony Brook, NY 11794,USA.

ORCID-Profile: Myvizhi Esai Selvan, Daniel I Nathan, Daniela Guisado, Giulia Collatuzzo, Sushruta Iruvanti, Paolo Boffetta, John Mascarenhas, Ronald Hoffman, Louis J Cohen, Bridget K Marcellino, Zeynep H Gümüş

Förderung

  • NCI NIH HHS
  • NIH HHS
  • Rainin Foundation
  • National Cancer Institute
  • National Institutes of Health

Zitieren

APA

Esai Selvan, M., Nathan, D. I., Guisado, D., Collatuzzo, G., Iruvanti, S., Boffetta, P., Mascarenhas, J., Hoffman, R., Cohen, L. J., Marcellino, B. K., & Gümüş, Z. H. (2025). Clonal Hematopoiesis of Indeterminate Potential in Crohn’s Disease and Ulcerative Colitis. Inflammatory Bowel Diseases, 31(8), 2123-2133. https://doi.org/10.1093/ibd/izae312

Vancouver

Esai Selvan M, Nathan DI, Guisado D, Collatuzzo G, Iruvanti S, Boffetta P, et al. Clonal Hematopoiesis of Indeterminate Potential in Crohn’s Disease and Ulcerative Colitis. Inflammatory Bowel Diseases. 2025;31(8):2123-2133. doi:10.1093/ibd/izae312

BibTeX
@article{EsaiSelvan2025,
  author = {Esai Selvan, Myvizhi and Nathan, Daniel I and Guisado, Daniela and Collatuzzo, Giulia and Iruvanti, Sushruta and Boffetta, Paolo and Mascarenhas, John and Hoffman, Ronald and Cohen, Louis J and Marcellino, Bridget K and Gümüş, Zeynep H},
  title = {Clonal Hematopoiesis of Indeterminate Potential in Crohn’s Disease and Ulcerative Colitis},
  journal = {Inflammatory Bowel Diseases},
  year = {2025},
  volume = {31},
  number = {8},
  pages = {2123--2133},
  doi = {10.1093/ibd/izae312}
}
Kostenlos starten →